Table 3 Clinical trials of adoptive cell therapy using CRISPR/Cas9 technology
From: CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy
Identifier | Phase | Target | Cancer type | Immunotherapy | Status | Last update |
|---|---|---|---|---|---|---|
NCT04637763 | Phase 1 | CD19 | B-cell non-Hodgkin lymphoma | Allogeneic CRISPR/Cas9-engineered T cells (CB-010) | Recruiting | 2023/6/15 |
NCT05643742 | Phase 1/2 | CD19 | B cell malignancies | Allogeneic CRISPR/Cas9-engineered T cells (CTX112) | Recruiting | 2023/3/31 |
NCT05662904 | Phase 1 | CD33 | AML | Allogeneic hematopoietic stem cell transplantation | Not yet recruiting | 2022/12/23 |
NCT05795595 | Phase 1/2 | CD70 | Solid tumors | Allogeneic CD70-directed CAR-T cell (CTX131) | Recruiting | 2023/4/19 |
NCT04502446 | Phase 1 | CD70 | T or B cell malignancies | Allogeneic CRISPR/Cas9-engineered T cells (CTX130) | Active | 2023/4/27 |
NCT04438038 | Phase 1 | CD70 | Renal cell carcinoma | Allogeneic CRISPR/Cas9-engineered T cells (CTX130) | Active | 2023/5/11 |
NCT04244656 | Phase 1 | BCMA | Multiple myeloma | Allogeneic CRISPR/Cas9-engineered T cells (CTX120) | Active | 2022/7/18 |
NCT04426669 | Phase 1/2 | CISH | Gastro-intestinal (GI) cancer | Genetically engineered TIL | Recruiting | 2023/3/3 |
NCT05566223 | Phase 1/2 | CISH | Non-small cell lung cancer | Genetically engineered TIL | Not yet recruiting | 2022/12/9 |
NCT04035434 | Phase 1/2 | Endo-TCR | B cell malignancies | Allogeneic CRISPR/Cas9-engineered T cells (CTX110) | Recruiting | 2023/7/17 |
NCT03166878 | Phase 1/2 | Endo-TCR/B2M | B-cell leukemia and lymphoma | UCART019 | Unknown | 2017/6/23 |
NCT03545815 | Phase 1 | Endo-TCR/PD-1 | Solid tumors | Anti-mesothelin CRISPR/Cas9-mediated CAR-T cell | Unknown | 2020/8/10 |
NCT03399448 | Phase 1 | Endo-TCR/PD-1 | Multiple myeloma; Melanoma; Synovial sarcoma | NY-ESO-1 TCR-T | Terminated | 2023/6/22 |
NCT03690011 | Phase 1 | CD7 | T-cell malignancies | Autologous T cells | Recruiting | 2023/4/28 |
NCT04264078 | Phase 1 | CD7/TRAC | T/NK cell hematologic malignancies | Allogeneic CAR-T cell | Unknown | 2021/6/28 |
NCT04557436 | Phase 1 | CD52/TRAC | B-ALL | Allogeneic CAR-T cell | Active | 2023/5/31 |
NCT03747965 | Phase 1 | PD-1 | Solid tumors | Mesothelin-directed CAR-T cell | Unknown | 2018/11/20 |
NCT04417764 | Phase 1 | PD-1 | Hepatocellular carcinoma | Engineered T cells | Recruiting | 2023/2/9 |
NCT02793856 | Phase 1 | PD-1 | Non-small cell lung cancer | Engineered T cells | Completed | 2021/1/12 |
NCT03081715 | Phase 1 | PD-1 | Esophageal cancer | Engineered T cells | Completed | 2019/6/12 |